



Meda comment on US rumors

With regard to the current rumors concerning Meda's US operations Meda states that business development is a natural part of the business model. This includes amongst others acquisitions, divestments, in-licensing and partnerships. Evaluating the US operations is one project. However, Meda's policy is not to comment on these activities.

For further inquiries, please contact:

Paula Treutiger, VP Corporate Communications & Sustainability

ph: +46 733-666 599

paula.treutiger@meda.se

Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on August 28, 2015, at 13:15 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.